This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Robert Dickinson
Site Head at Novartis Biome San Francisco


Robert currently serves as the site head of the Novartis Biome, a digital health accelerator in San Francisco.  He is also a Principle at Spindle Life Sciences Consulting, a boutique consultancy.  He has 20 years of life sciences commercial strategy and operations experience.  Before his current roles, he had client-facing responsibilities at Accenture, where he drove partnerships with large biotechnology and medical device companies to solution and deliver complex commercial transformation programs.

Prior to Accenture, Robert held positions at ZS Associates and Deloitte Consulting.  During his consulting career, he has had client development and delivery leadership responsibility for 200+ consulting projects, all of which were in the life sciences space.  His work has spanned portfolio strategy, customer strategy, product commercialization, life cycle management, commercial operations, and related areas. 

He is particularly passionate about applying disruptive opportunities in digital health, beyond-the-medicine solutions, precision health analytics, device connectivity, volume-to-value shifting/health economics, patient-centric approaches, and alternative site care.  He has authored scores of articles and spoken at numerous trade events about these topics.  His views about various healthcare trends have also been quoted in PharmaVoice Magazine, Oncology & Biotech News, Time Magazine, and USA Today.

Robert mentors life sciences and digital health entrepreneurs as an expert advisor working with several Bay Area incubators, including CLSI/FAST, Plug and Play, and QB3.  He also occasionally makes angel investments in early stage companies.

Robert began his career as a bench researcher in the Pharmacological Sciences organization of Genentech, where he focused on late stage development of Herceptin.  He holds a BA in Molecular & Cell Biology from the University of California, Berkeley.

Agenda Sessions

  • Go-to-Market LIVE: Getting from concept to commercialization - Parc 55


Speakers at this event